120 related articles for article (PubMed ID: 37866625)
1. Physiologically-Based Modeling and Interspecies Prediction of Cisplatin Pharmacokinetics.
Zang X; Kagan L
J Pharm Sci; 2024 Jan; 113(1):158-166. PubMed ID: 37866625
[TBL] [Abstract][Full Text] [Related]
2. Interspecies prediction of pharmacokinetics and tissue distribution of doxorubicin by physiologically-based pharmacokinetic modeling.
Lee JB; Zhou S; Chiang M; Zang X; Kim TH; Kagan L
Biopharm Drug Dispos; 2020 Apr; 41(4-5):192-205. PubMed ID: 32342986
[TBL] [Abstract][Full Text] [Related]
3. Physiologically-based modeling and interspecies prediction of paclitaxel pharmacokinetics.
Zang X; Kagan L
J Pharmacokinet Pharmacodyn; 2018 Aug; 45(4):577-592. PubMed ID: 29671170
[TBL] [Abstract][Full Text] [Related]
4. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
[TBL] [Abstract][Full Text] [Related]
5. Physiological pharmacokinetic modeling of cis-dichlorodiammineplatinum(II) (DDP) in several species.
King FG; Dedrick RL; Farris FF
J Pharmacokinet Biopharm; 1986 Apr; 14(2):131-55. PubMed ID: 3746636
[TBL] [Abstract][Full Text] [Related]
6. Physiologically based pharmacokinetic model of amphotericin B disposition in rats following administration of deoxycholate formulation (Fungizone®): pooled analysis of published data.
Kagan L; Gershkovich P; Wasan KM; Mager DE
AAPS J; 2011 Jun; 13(2):255-64. PubMed ID: 21431453
[TBL] [Abstract][Full Text] [Related]
7. Prediction of Human Distribution Volumes of Compounds in Various Elimination Phases Using Physiologically Based Pharmacokinetic Modeling and Experimental Pharmacokinetics in Animals.
Shimizu H; Yoshida K; Nakada T; Kojima K; Ogasawara A; Nakamaru Y; Yamazaki H
Drug Metab Dispos; 2019 Feb; 47(2):114-123. PubMed ID: 30420404
[TBL] [Abstract][Full Text] [Related]
8. Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children.
Centanni M; Zaher O; Elhad D; Karlsson MO; Friberg LE
Cancer Chemother Pharmacol; 2024 May; ():. PubMed ID: 38782791
[TBL] [Abstract][Full Text] [Related]
9. Prediction of Human Pharmacokinetics of E0703, a Novel Radioprotective Agent, Using Physiologically Based Pharmacokinetic Modeling and an Interspecies Extrapolation Approach.
Ge YX; Zhang Z; Yan JY; Ma ZC; Wang YG; Xiao CR; Zhuang XM; Gao Y
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474292
[TBL] [Abstract][Full Text] [Related]
10. Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans.
Luttringer O; Theil FP; Poulin P; Schmitt-Hoffmann AH; Guentert TW; Lavé T
J Pharm Sci; 2003 Oct; 92(10):1990-2007. PubMed ID: 14502539
[TBL] [Abstract][Full Text] [Related]
11. Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model.
Zhao J; Cao Y; Jusko WJ
Pharm Res; 2015 Oct; 32(10):3269-81. PubMed ID: 25939552
[TBL] [Abstract][Full Text] [Related]
12. Human plasma concentrations of cytochrome P450 probe cocktails extrapolated from pharmacokinetics in mice transplanted with human hepatocytes and from pharmacokinetics in common marmosets using physiologically based pharmacokinetic modeling.
Utoh M; Suemizu H; Mitsui M; Kawano M; Toda A; Uehara S; Uno Y; Shimizu M; Sasaki E; Yamazaki H
Xenobiotica; 2016 Dec; 46(12):1049-1055. PubMed ID: 26916082
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis.
Peters SA
Clin Pharmacokinet; 2008; 47(4):261-75. PubMed ID: 18336055
[TBL] [Abstract][Full Text] [Related]
14. Across-species meta-analysis of dexamethasone pharmacokinetics utilizing allometric and scaling modeling approaches.
Song D; Jusko WJ
Biopharm Drug Dispos; 2021 May; 42(5):191-203. PubMed ID: 33638217
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and toxicodynamics of cisplatin and its metabolites in rats: relationship between renal handling and nephrotoxicity of cisplatin.
Hanada K; Ninomiya K; Ogata H
J Pharm Pharmacol; 2000 Nov; 52(11):1345-53. PubMed ID: 11186242
[TBL] [Abstract][Full Text] [Related]
16. Effects of sodium thiosulfate on the pharmacokinetics of unchanged cisplatin and on the distribution of platinum species in rat kidney: protective mechanism against cisplatin nephrotoxicity.
Nagai N; Hotta K; Yamamura H; Ogata H
Cancer Chemother Pharmacol; 1995; 36(5):404-10. PubMed ID: 7634382
[TBL] [Abstract][Full Text] [Related]
17. Application of the Tissue Composition-Based Model to Minipig for Predicting the Volume of Distribution at Steady State and Dermis-to-Plasma Partition Coefficients of Drugs Used in the Physiologically Based Pharmacokinetics Model in Dermatology.
Poulin P; Collet SH; Atrux-Tallau N; Linget JM; Hennequin L; Wilson CE
J Pharm Sci; 2019 Jan; 108(1):603-619. PubMed ID: 30222978
[TBL] [Abstract][Full Text] [Related]
18. Physiologically based pharmacokinetics (PBPK).
Espié P; Tytgat D; Sargentini-Maier ML; Poggesi I; Watelet JB
Drug Metab Rev; 2009; 41(3):391-407. PubMed ID: 19601719
[TBL] [Abstract][Full Text] [Related]
19. Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles.
Peters SA
Clin Pharmacokinet; 2008; 47(4):245-59. PubMed ID: 18336054
[TBL] [Abstract][Full Text] [Related]
20. Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model.
Yamazaki S; Skaptason J; Romero D; Vekich S; Jones HM; Tan W; Wilner KD; Koudriakova T
Drug Metab Dispos; 2011 Mar; 39(3):383-93. PubMed ID: 21098644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
